Zimbabwe has rejected a major American healthcare agreement valued at 367 million US dollars (£272m) spanning five years over Washington's demand for confidential biological samples.
The decision came to light after a government memo from December was leaked, indicating that Head of State Emmerson Mnangagwa deemed the agreement was "unbalanced".
A government representative has since explained that the US was seeking biological samples for research and commercial purposes while was unwilling to share the benefits from any future vaccines.
"We are forced to start the challenging and unfortunate process of winding down our health assistance in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont publicly.
Her embassy noted the United States had furnished more than $1.9bn for health programmes to Zimbabwe during the past twenty years.
A medical body in Zimbabwe has urged further negotiations to secure a agreement agreeable to all parties so the nation's vital HIV treatment initiative can proceed.
Broader Background
Zimbabwe's decision follows a similar situation in neighbouring Kenya, where a court suspended a similar deal with the US following legal challenges were filed about the security of Kenyans' medical information.
After resuming office recently, US President Donald Trump has slashed overseas assistance and shut down the key foreign aid agency.
The agency had overseen assistance for the American government, but Trump stated its expenditure was "inefficient" and his government was pursuing direct bilateral agreements to enhance transparency and accountability.
According to statements, Sixteen African countries have to date signed similar agreements, representing over $18.3bn in new funding.
Specifics of the Declined Deal
This assistance for Zimbabwe was intended to funded "tackling HIV/Aids, tuberculosis, malaria, maternal and child health, and disease outbreak preparedness.
"We are confident this cooperation could have provided immense advantages for the people of Zimbabwe, particularly the 1.2 million men, women and children presently on HIV treatment via US-supported programmes," the Ambassador commented.
However, government spokesperson Nick Mangwana said the proposed deal was "unequal".
"Our nation was requested to share its genetic material and health information indefinitely, without any equivalent promise of access to any scientific breakthroughs – like vaccines, diagnostics, or treatments – that might be developed from that provided information," he stated.
"In essence, our country would supply the raw materials for scientific discovery with no certainty that the end products would be accessible to our citizens should a new disease outbreak arise."
Sovereignty and International Frameworks
Mangwana further noted that the US's withdrawal from the global health body and its pursuit of bilateral health agreements were disrupting structures already set up via the global health agency.
The spokesperson cited its Pathogen Access and Benefit Sharing scheme designed to manage potential global health emergencies.
"This mechanism is designed to guarantee that when a nation provides its samples, the resulting advantages – such as medicines and cures – are shared equitably, not monopolised exclusively by those with the capability to create them."
Zimbabwe's reservations regarding the US deal "are not meant as hostility towards the US," Mangwana stressed.
"We are open to further dialogue with our American counterparts on how subsequent co-operation might be designed in a manner that honours the independence and dignity of each country."
Medical Community Response
Medical experts said it acknowledged the official position, but recommended that talks should continue since much of the nation's HIV programmes were funded by international support.
"Where technical issues arise, including those relating to information security or implementation frameworks, these can frequently be resolved via technical clarification and negotiated safeguards," the group added.
This impasse highlights the continuing challenges between accepting much-needed international aid and protecting national sovereignty in an increasingly data-driven world.